The information in this section is intended for visitors outside the United States.
Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8
Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Gilead Sciences and Kite to Acquire Cell Design Labs
Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6
Gilead Sciences Announces Fourth Quarter 2017 Dividend
Gilead Sciences Announces Third Quarter 2017 Financial Results
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
Gilead Sciences to Present at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7
Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017
Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire
Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection
Gilead Prices $3 Billion of Senior Unsecured Notes
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11
Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3
Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
Kite Reports Second Quarter 2017 Financial Results
Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
Kite to Report Second Quarter 2017 Financial Results on August 8, 2017
Kite to Present at August 2017 Investor Conference
Kite Files the Industry's First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C
Gilead Sciences Announces Third Quarter 2017 Dividend
Gilead Sciences Announces Second Quarter 2017 Financial Results
Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute
U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
U.S. Patent Office to Confirm Kite's Seminal Eshhar CAR-T Patent
Kite Named to the MIT Technology Review's Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Kite to Present at June 2017 Investor Conferences
Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting
Kite Reports First Quarter Financial Results
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
Gilead Sciences Announces First Quarter 2017 Financial Results
Gilead Sciences Announces Second Quarter 2017 Dividend
Kite to Report First Quarter 2017 Financial Results on May 8, 2017
Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
Kite Wins ‘Clinical Trial Result of the Year' for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards
Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting
Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
Kite to Present Two Plenary Presentations from the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting
Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors
Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy
Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kite to Present at March 2017 Investor Conferences
Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered T-Cell Therapies for Treatment of Cancers in China
Kite Announces Commencement of Public Offering of Common Stock
Kite Announces Pricing of Public Offering of Common Stock
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
Kite Reports Fourth Quarter and Full Year 2016 Financial Results
Kite to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize Axicabtagene Ciloleucel (KTE-C19) in Japan
Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors
Kite Pharma to Present at the 35th Annual J.P. Morgan Healthcare Conference
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6